NeuroSense Therapeutics Ltd. Warrant
NRSNWStock
$0.10
Market Cap—
P/E—
Div yield—
Beta1.03
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-91.63%
Price vs S&P 500 (4W)46.90%
VGM Score14.89
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRSNWNeuroSense Therapeutics Ltd. Warrant | — | — | F | $0.10 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
NeuroSense Therapeutics is a clinical-stage biotechnology company developing treatments for neurodegenerative diseases including ALS, Alzheimer's, and Parkinson's disease. Its lead product candidate, PrimeC, is an extended-release oral formulation combining two FDA-approved generic drugs in a fixed-dose combination. The company aims to repurpose existing medications to address unmet needs in neurodegenerative disease treatment.